TrialEBioMedicine2026

A randomized, observer-blind, phase 1 study of immune responses to three human adenovirus type 26 vector-based vaccines.

Nina Hertoghs et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.